Latest From Genexine Inc.
Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares.
Coronavirus Update: Rapid Japan Approval For Remdesivir, Combination With Lilly's Olumiant Is Next Hope
Plus: Chugai enters into Singapore research alliance, Korean consortium reports vaccine progress.
Genexine is poised to continue to focus on developing therapeutic DNA vaccine GX-188E as combination therapy, following Phase II interim results in advanced cervical cancer that show impressive clinical benefit over pembrolizumab monotherapy.
Japanese bioventure goes down the DNA vaccine route, along with several others worldwide, pointing to potential development speed and safety advantages.
- Large Molecule
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Genexine Co. Ltd.
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Genexine Inc.
- Senior Management
Young Chul Sung , PhD, CTO
Tae Kim, PhD, VP, Clin. Operations
Kyudon Kim, EVP, COO
- Contact Info
Phone: (82) 31 628 3200
700 Daewangpangyo-ro, Korea Bio Park
Bundang-gu, Seongnam-si,, 13488